Northwest Wealth Management LLC Has $316,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Northwest Wealth Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% in the first quarter, Holdings Channel reports. The institutional investor owned 2,000 shares of the company’s stock after selling 204 shares during the period. Northwest Wealth Management LLC’s holdings in Johnson & Johnson were worth $316,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Etesian Wealth Advisors Inc. grew its position in Johnson & Johnson by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 11,093 shares of the company’s stock worth $1,737,000 after buying an additional 73 shares in the last quarter. Oak Harvest Investment Services lifted its position in shares of Johnson & Johnson by 5.2% during the 4th quarter. Oak Harvest Investment Services now owns 56,509 shares of the company’s stock valued at $8,857,000 after acquiring an additional 2,790 shares during the period. Clearview Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after purchasing an additional 64 shares in the last quarter. Stableford Capital II LLC increased its position in shares of Johnson & Johnson by 1.9% in the fourth quarter. Stableford Capital II LLC now owns 14,896 shares of the company’s stock worth $2,400,000 after purchasing an additional 284 shares during the period. Finally, Kure Advisory LLC raised its stake in Johnson & Johnson by 5.4% in the fourth quarter. Kure Advisory LLC now owns 2,752 shares of the company’s stock valued at $431,000 after purchasing an additional 141 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 2.2 %

NYSE JNJ traded up $3.42 during trading hours on Thursday, reaching $159.70. The company’s stock had a trading volume of 10,014,267 shares, compared to its average volume of 7,340,644. The firm has a fifty day simple moving average of $148.62 and a 200-day simple moving average of $153.25. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The stock has a market cap of $384.35 billion, a P/E ratio of 9.96, a P/E/G ratio of 2.49 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter last year, the firm earned $2.80 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.11%. Johnson & Johnson’s payout ratio is 30.92%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on JNJ shares. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 18th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $160.00 to $150.00 in a research note on Tuesday. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.